▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1722 by analyst upside · 2026-06-27
BHVN
Biohaven Ltd.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+37.1%
implied upside to consensus target
Current Price $15.83
Consensus Target $21.71
Bull Target $50.0
Bear Target $9.0
Analysts Covering 17
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
8
Hold
5
Sell
0
52-Week Low $7.48
52-Week High $18.57
YTD Return +46.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -8.1x
EPS (TTM) $-5.75
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.48
52-Week High $18.57
Current Price $15.83
Bear Target $9.0
Bull Target $50.0
● Now $15.83 ● Target $21.71
TRADING DATA
Avg Volume 2.6M
YTD Return +46.0%
Analyst Count 17
Consensus Buy
Upside to Target +37.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Biohaven Ltd. (BHVN) is currently trading at $15.83 with a Wall Street consensus price target of $21.71, implying potential upside of 37.1% over the next 12 months. 17 analysts currently cover BHVN, with a consensus rating of Buy - 71% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $9.0.

BHVN operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 46.0% year-to-date and is currently trading near the upper end of its 52-week range of $7.48 – $18.57.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PBH +35.2%
Prestige Consumer Healthcare Inc.
$2B · P/E 12.6x · Buy
HRMY +25.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 14.3x · Buy
ANIP +33.4%
ANI Pharmaceuticals, Inc.
$2B · P/E 21.3x · Buy
ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy
UFPT +24.9%
UFP Technologies, Inc.
$2B · P/E 29.6x · Underperform

RECENT ANALYST CALLS

Upgrade/downgrade history for BHVN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Neutral → Neutral 2026-05-26 31% win rate (48 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-05-13 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-05 Building track record
Citigroup — Reiterated
Buy → Buy 2026-04-02 Building track record
TD Cowen — Reiterated
Buy → Buy 2026-03-11 Building track record
HC Wainwright & Co. — Reiterated
Neutral → Neutral 2026-03-04 31% win rate (48 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-03-03 Building track record
RBC Capital ↑ Upgrade
Sector Perform → Outperform 2026-01-21 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
36
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →